Guardant Health Reaches New 52-Week High of $95.88, Up 207%

Guardant Health, Inc. has reached a significant milestone by hitting a new 52-week high of USD 95.88 on October 30, 2025. This achievement underscores the company's remarkable performance over the past year, with a staggering increase of 207.42%, significantly outpacing the S&P 500's growth of 18.13% during the same period.
As a small-cap player in the Pharmaceuticals & Biotechnology industry, Guardant Health has demonstrated strong financial metrics, including a return on equity of 138.84%. However, it is important to note that the company is currently loss-making, as indicated by the absence of a price-to-earnings ratio. The market capitalization stands at USD 7,503 million, reflecting its position within the small-cap segment.

Despite not offering dividends, Guardant Health's performance indicators highlight its potential within the industry. The stock's previous 52-week low was recorded at USD 21.85, marking a significant turnaround in its market position. This upward trajectory may attract attention as the company continues to navigate the dynamic landscape of the pharmaceuticals and biotechnology sector.